<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617561</url>
  </required_header>
  <id_info>
    <org_study_id>PBC With AIH Features II</org_study_id>
    <nct_id>NCT04617561</nct_id>
  </id_info>
  <brief_title>Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II</brief_title>
  <official_title>Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II：A Randomized Controlled Open-label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled open-label clinical trial of ursodeoxycholic acid combined with low&#xD;
      dose glucocorticoid in the treatment of PBC With AIH Features II to asses efficacy and&#xD;
      safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical remission</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The percentage of patients in biochemical remission, defined as normalization of serum ALT and IgG levels after treatment, per treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial remission</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Partial remission, defined as ALT or AST serum levels &gt;1x Upper Limit of Normal (ULN) and &lt;2x ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal response</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Minimal response, defined as decrease of ALT or AST serum levels but still &gt;2x ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>up to 12 months</time_frame>
    <description>defined as no improvement or increase of ALT or AST serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT,AST,IgG</measure>
    <time_frame>baseline and month 3,6,12</time_frame>
    <description>serum ALT,AST and IgG levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of immune cells</measure>
    <time_frame>baseline and month 12</time_frame>
    <description>percentage of T cells, cDC, MDSC, Treg, Breg, plasma cells, NK, NKT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side-effects</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Drug related side-effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hepatitis, Autoimmune</condition>
  <condition>Primary Biliary Cholangitis</condition>
  <arm_group>
    <arm_group_label>Ursodeoxycholic Acid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ursodeoxycholic Acid 13-15mg/kg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursodeoxycholic Acid+Low Dose Glucocorticoid group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ursodeoxycholic Acid 13-15mg/kg/d+Methylprednisolone 12mg/d in induction period and 2-4mg/d in maintenance period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid</intervention_name>
    <description>Participants received Ursodeoxycholic acid (13-15mg/kg/d po.)</description>
    <arm_group_label>Ursodeoxycholic Acid group</arm_group_label>
    <other_name>UDCA;Ursofalk(250mg*25,Losan Pharma GmbH)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)</intervention_name>
    <description>Participants received Methylprednisolone (12mg/d po. in induction and 2-4mg/d in maintenance) combined with Ursodeoxycholic acid (13-15mg/kg/d po.)</description>
    <arm_group_label>Ursodeoxycholic Acid+Low Dose Glucocorticoid group</arm_group_label>
    <other_name>Medrol（4mg*30,pfizer ltalia srl)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18-75 years;&#xD;
&#xD;
          2. The diagnosis of PBC is clear and does not meet the Paris criteria for diagnosing PBC&#xD;
             overlap AIH, but it needs to meet 3xULN &lt; ALT &lt; 5xULN or 3xULN &lt; AST &lt; 5xULN or&#xD;
             1.3xULN &lt; IgG &lt; 2xULN, and liver pathological biopsy excludes moderate or higher&#xD;
             interface inflammation;&#xD;
&#xD;
          3. Agreed to participate in the trial, and assigned informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The presence of hepatitis A, B, C, D, or E virus infection;&#xD;
&#xD;
          2. Patients with presence of cirrhosis;&#xD;
&#xD;
          3. Patients with presence of fulminant liver failure;&#xD;
&#xD;
          4. Liver damage caused by other reasons: such as primary sclerosing cholangitis,&#xD;
             non-alcoholic steatohepatitis, drug induced liver disease or Wilson's disease;&#xD;
             Pregnant and breeding women and women of childbearing age in need of reproduction;&#xD;
&#xD;
          5. Severe disorders of other vital organs, such as severe heart failure, cancer;&#xD;
&#xD;
          6. Parenteral administration of blood or blood products within 6 months before screening;&#xD;
&#xD;
          7. Recent treatment with drugs having known liver toxicity;&#xD;
&#xD;
          8. Taken part in other clinic trials within 6 months before enrollment.&#xD;
&#xD;
          9. patients with contraindications of glucocorticoid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Gastroenterology &amp; Hepatology,West China Hospital,Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yang, MD</last_name>
      <phone>+86 18980601276</phone>
      <email>yangli_hx@scu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Chen Huang</last_name>
      <phone>+86 18328089415</phone>
      <email>huangchen0323@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chen Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Li Yang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Glucocorticoid</keyword>
  <keyword>Ursodeoxycholic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

